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Abstract 
We used in vivo electrophysiology and a model of more persistent nociceptive inputs 
to monitor spinal cord neuronal activity in anaesthetized rats to reveal the 
pharmacology of enhanced pain signaling. The study showed that all responses were 
blocked by non-selective antagonism of glutamate receptors but a selective and 
preferential role of the N-methyl-d-aspartate (NMDA) receptor in the prolonged 
plastic responses was clearly seen. The work lead to many publications, initially 
preclinical but increasingly from patient studies, showing the importance of the 
NMDA receptor in central sensitisation within the spinal cord and how this could 
relate to persistent pain states.  
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Subcutaneous injection of formalin into the hindpaw peripheral receptive field of 
deep dorsal horn multireceptive (convergent) nociceptive neurones was used to 
produce a prolonged (1 h) activation of the cells. This chemical noxious stimulus 
produced a first peak of firing which lasted 10 min followed by a second peak of 
prolonged activity which was monitored for 50 min. γ-d-glutamylglycine (DGG), a 
non-selective N-methyl-d-aspartate (NMDA) and quisqualate/kainate (non-NMDA) 
receptor antagonist was applied intrathecally both as a pretreatment and after the 
formalin. A complete abolition of both peaks of the formalin response was produced 
by DGG pretreatment (1000 μg) (n = 4). This dose produced profound inhibition of 
the acute C-fibre evoked responses of the same cells. However, no inhibitions were 
produced when the antagonist was applied once the formalin response had 
developed (n = 4). The selective NMDA receptor antagonist 5-amino-
phosphonovaleric acid (AP5) was administered intrathecally (250 and 500 μg) as a 40 
min pretreatment and caused a small inhibition of the first peak but a marked dose-
related reduction in the second prolonged phase (n = 7). AP5 did not influence the C-
fibre inputs onto the cells. The non-competitive NMDA receptor channel blockers, 
ketamine and MK801, were administered i.v. during the second phase of firing. 
Ketamine (1-8 mg/kg) caused a short-lasting but marked and dose-related inhibition 
of the neuronal responses to formalin (n = 11). MK801 (0.5-1 mg/kg) resulted in a 
prolonged inhibition of cell firing during the second phase of the response (n = 11). 
When administered intravenously as a 30 min pretreatment, MK801 (0.5-1 mg/kg) 
produced a dose-related inhibition of the second phase of firing with only a small 
inhibition of the first phase. Finally, blockade of peripheral afferent activity during 
the first peak by 2% lignocaine administered into the site of the formalin injection 
did not alter the second peak in any way (n = 10). It therefore appears that the 
afferent barrage produced by formalin induces NMDA mediated central activity over 
a relatively short time span and that once induced this activity could be one basis for 
changes in nociception and its modulation during longer-term pain states.  
 
 
During the late 1980’s the idea that pain inputs could be amplified in the periphery 
was well established [Woolf 1983] but the concept of amplification occurring at the 
level of the spinal cord was just beginning to be considered. The idea that pain 
wasn’t all in the periphery; that it was changeable and not immutable and arose as a 
result of changes in the spinal cord was a fundamental shift in thinking.  Such plastic 
changes within the central nervous system had already been demonstrated in the 
hippocampus; electrophysiological recordings had been used to reveal that long-
term potentiation (LTP) was a model system for examining activity-driven 
amplification of signals and that this phenomenon was involved in spatial memory 
formation [see Collingridge and Bliss 1995]. From these studies we knew, therefore, 
that the high frequency stimulation used to induce LTP elicited enough 
depolarization in the post-synaptic neurone to recruit glutamate NMDA receptors 
and that this resulted in a long-term amplification in the pathway [see Ji et al 2003].  
Furthermore, the availability of antagonists at the NMDA receptor allowed 
pharmacological dissection of this phenomenon. There was some evidence that 
glutamatergic inputs into the spinal cord were capable of activating NMDA receptors 
since a previous study of ours, [Dickenson and Sullivan 1987] coincident with a great 
paper by Davies and Lodge [Davies and Lodge 1987]], showed that low frequency 
stimulation produced a short duration potentiation of signals at spinal cord dorsal 
horn neurons (termed ‘wind up’), and this was prevented by blocking the NMDA 
receptor. 
 
So, in 1990 not much was known about central hypersensitivity in pain or the 
neuronal substrates that could be involved. In order to understand more, we used a 
technique that allowed us to extracellularly record the firing activity of dorsal horn 
neurones directly, in vivo in the anesthetized rat.  The lab was well placed to use this 
technique as Tony Dickenson had learnt in vivo extracellular electrophysiology 
recording in Paris as a post-doc [Le Bars et al 1979] and had brought the technique 
to UCL when he established his own lab in 1983. Previously we had used this 
technique to examine the inhibitory controls exerted by the different opioid 
receptors on dorsal horn activity in response to stimulation [Dickenson and Sullivan 
1987]. We now felt that it could be used to explore in more depth the excitatory 
inputs and, coupled with pharmacological tools, we could tease out what were the 
transforming events that might lead to central sensitization. 
 
Unlike LTP, which generally requires high frequency stimulation to be elicited, we 
wanted to use a more natural stimulus. The subcutaneous injection of formalin into 
the hindpaw had previously been used as a behavioural stimulus and shown to 
produce pain-related behaviour that lasted for an hour [Coderre et al 1990], which is 
much longer than the few seconds of stimuli generally used for algesia tests such as 
the tail-flick. It was hardly chronic pain but the duration of the effect allowed for 
pharmacological manipulations and a more persistent stimulus.  The work was done 
by two young fantastic scientists, Jane Haley, who was doing a PhD and Ann Sullivan 
who joined as a technician but who also gained a PhD.  The formalin response was 
generally very reliable and I recall that the study was finished in a short period of 
time. We chose Brain Research for publication since we felt that the concept was an 
important one and might resonate across many neuroscience domains.  
 
So what was found?  
Following a single bolus injection of formalin into the hindpaw, we saw a biphasic 
pattern in the activity in the dorsal horn neurons: an immediate, acute, phase of 
activity that rapidly faded and was then followed by a delayed but more sustained 
second phase and this mirrored the behavioural response.  Since glutamate is the 
major transmitter in pain transmitting C-fibres, a non-selective antagonist of all non-
NMDA receptors abolished both electrically stimulated C-fibre activity and the 
formalin responses. But intriguingly, it failed as a post-treatment. The theory that 
the second, prolonged, phase of the formalin response was due to NMDA receptor 
activation was confirmed when the antagonist, AP5, selectively blocked this 
response but was without effect on acute pain responses. This strongly suggested a 
role of the NMDA receptor in the hypersensitivity at the spinal level. We then further 
verified this by using two more NMDA channel blockers given systemically, MK-801 
and ketamine and validated the previous findings. Finally, we used a rather neat 
manipulation – we blocked the peripheral input with local anaesthetic so preventing 
the first peak and showed the second persistent NMDA mediated response was 
unchanged. 
Thus the paper showed, for the first time, that spinal hypersensitivity uses NMDA 
mediated events when pain becomes persistent and that this plasticity is rapidly 
induced. 
 
So what happened next? 
The paper was seminal in translational research on pain.  The concept that spinal 
hyperexcitability could be mediated centrally, via the NMDA receptor, and could be 
modulated by an already-licensed pharmaceutical – ketamine - lead to the use of 
this drug in pain patients [Dickenson 1990, Woolf 2011, see Fiorelli et al 2015, ]. The 
description neural plasticity translated to many pain patient groups and has since 
been shown to be a marker for persistent pain. In more general terms, the idea that 
pain could be enhanced by central mechanisms has been important in helping health 
care professionals to believe that patients can experience high levels of pain despite 
minor peripheral signs.  
Within a few years, the central hypersensitivity theory was being used to explore 
novel therapies. We now know that the peripheral consequences of nerve injury and 
inflammation are very different and that the short term inflammatory models such 
as formalin are not necessarily indicative of persistent inflammation such as arthritis, 
for which models now exist. Although there were models of nerve injury available 
from the early 90s, these were hardly characterized in terms of drug effects. 
However, as a result of both animal models and human data, central 
hyperexcitability it is now recognized that as a relatively common event in many 
pains of different origins [Baron et al 2013, Clauw 2015, Dickenson 1990, Woolf 
2011]  
 
Although most published studies on spinal hypersensitivity for the next decade were 
from academics, one key paper from the pharmaceutical industry was published in 
1997 [Hunter et al 1997]. Hunter et al was a landmark paper but, very tellingly, the 
title was “The effect of novel anti-epileptic drugs in rat experimental models of acute 
and chronic pain”. So, even here, the concept that acute tests may not be predictive 
of persistent pains is acknowledged. They further state, “This ability to acutely 
reverse a prominent manifestation of neuronal sensitization demonstrates the 
potential of these drugs as analgesics for the relief of chronic pain following tissue or 
nerve injury. Moreover, the negligible effect of these drugs against an acute, high 
threshold thermal noxious stimulus suggests a selective interaction with pathways 
associated with pathophysiological events rather than with normal sensory 
nociceptive function.” So following our study and others using the formalin test, and 
based on the differential effects of drugs if given before or after the start of the pain 
state, the concept of preemptive analgesia arose and still is a key issue in patients 
[see Fiorelli et al 2015].  
 
Today, the other concepts from the paper still hold. A series of reviews on the 
subject by Woolf and colleagues, who also carried out a series of studies on the 
substrates for central sensitization, followed and a recent review covers the clinical 
implications of the findings on neuronal plasticity in spinal pain signaling [Baron et al 
2013, Clauw 2015, Dickenson 1990, Woolf 2011] . One important point from the 
paper was that peripheral drives were absolutely required for the manifestation of 
excitability - since lidocaine blocked the neuronal responses for the duration of its 
action, but as the effect wore off, the central neurones regained their activity. Thus, 
these pain related events would seem to differ from LTP where the enhanced 
activity in hippocampal circuits remains for hours after the conditioning stimulus 
irrespective of the continuation of stimulus input [Collingridge and Bliss 1995]. This 
makes sense for pain processes since it is very clear that, where possible, blocking 
the peripheral inputs by local or regional anaesthesia can be effective therapies 
[Baron et al 2013]. 
 
The presence of central sensitization is a risk factor for chronic post-surgical pain in 
those undergoing certain surgical procedures [Petersen et al 2015] and the concept 
has been shown to relate to pain in many patient groups [Baron et al 2013]. For 
example, the spread of pain around the original site of injury and abnormal wind-up 
can be clearly seen in patients with osteoarthritis. Ketamine is used in patients, often 
during surgical procedures to dampen hyperexcitability and in patients with cancer 
pain. The problematic side effects of the drugs can be circumvented in the former 
setting where the patients are under anaesthesia but attempts to avoid interference 
with forebrain NMDA receptor function have not materialized so that sedation and 
cognitive side-effects still prevail. Promising attempts to produce NR2B blockers did 
not lead to drugs for patients but there is promise in other drugs that target effects 
downstream of the NMDA receptor, including interference with scaffolding proteins 
and the production of nitric oxide in neurones, which may allow uncoupling of the 
pathophysiological adverse effects of the receptor function leaving more 
physiological functions unaltered [D’Mello et al 2011]. However, there are drugs that 
indirectly modulate these NMDA functions in pain. For example, the signs of central 
sensitization can be seen in the brain by fMRI imaging and this activity can be 
modulated by the drug gabapentin that interacts with spinal calcium channel 
functions. Consequently, the presence of central sensitization predicts the actions of 
the drug. 
 
So, the intervening 25 years have seen major steps to understanding pain, and in 
translating basic science to the patient and improving treatments. We are proud that 
our paper has been part of this process. 
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